Low-dose belantamab mafodotin (belamaf) in combination with nirogacestat vs belamaf monotherapy in patients with relapsed/refractory multiple myeloma (RRMM): phase I/II DREAMM-5 platform sub-study 3

被引：0

作者：

Leypoldt, L. ^{[1
]}

Callander, N. S. ^{[2
]}

Richardson, P. G. ^{[3
]}

Hus, M. ^{[4
]}

Ribrag, V. ^{[5
]}

Lopez, J. M. ^{[6
]}

Kim, K. ^{[7
]}

Lee, J. H. ^{[8
]}

Dimopoulos, M. A. ^{[9
,10
]}

Schjesvold, F. ^{[11
,12
]}

Facon, T. ^{[13
]}

Jo, J. -C. ^{[14
]}

Min, C. -K. ^{[15
]}

Mielnik, M. ^{[4
]}

Cheng, S. ^{[16
]}

Smith, L. M. ^{[16
]}

Breitbach, C. J. ^{[16
]}

Brawley, C. ^{[17
]}

Sembhi, H. ^{[17
]}

LaMacchia, J. ^{[18
]}

Grosicki, S. ^{[19
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[2] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Katedra & Klin Hematoonkol & Transplantacji Szpik, Lublin, Poland

[5] Inst Gustave Roussy, Villejuif, France

[6] Univ Complutense Madrid, Hosp Univ 12 Octubre, Dept Hematol, CNIO,CIBERONC, Madrid, Spain

[7] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[8] Gachon Univ, Gachon Univ Gil Med Ctr, Coll Med, Incheon, South Korea

[9] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece

[10] Alexandra Hosp, Athens, Greece

[11] Oslo Univ Hosp, Oslo Myeloma Ctr, Dept Hematol, Oslo, Norway

[12] Univ Oslo, KG Jebsen Ctr B Cell Malignancies, Oslo, Norway

[13] Lille Univ Hosp, Dept Haematol, Lille, France

[14] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Ulsan, South Korea

[15] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea

[16] SpringWorks Therapeut, Stamford, CT USA

[17] GSK, Stevenage, Herts, England

[18] GSK, Waltham, MA USA

[19] Med Univ Silesia, Dept Hematol & Canc Prevent, Katowice, Poland

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P330

引用

页码：176 / 177

页数：2

共 50 条

[41] COST-EFFECTIVENESS OF BELANTAMAB MAFODOTIN (BELAMAF) VS. MELPHALAN FLUFENAMIDE IN COMBINATION WITH DEXAMETHASONE (MEL plus DEX) IN HEAVILY PRE-TREATED RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: A US PAYER PERSPECTIVE
Yang, J.
Barthold, D.
VALUE IN HEALTH, 2022, 25 (07) : S362 - S362
[42] DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B- Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Trudel, Suzanne
Davis, Randy
Lewis, Nicole M.
Bakshi, Kalpana K.
Chopra, Bikramjit
de Oca, Rocio Montes
Ferron-Brady, Geraldine
Eliason, Laurie
Kremer, Brandon E.
Gupta, Ira
Wu, Frank S.
BLOOD, 2020, 136
[43] Pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM): Randomized, phase 3 KEYNOTE-183 study
Ocio, E. M.
Shah, J.
Jagannath, S.
Mateos, M-V
Palumbo, A.
Kher, U.
Marinello, P.
San Miguel, J.
ANNALS OF ONCOLOGY, 2016, 27
[44] DREAMM-8: A phase III study of the efficacy and safety of belantamab mafodotin with pomalidomide and dexamethasone vs pomalidomide plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
Trudel, Suzanne
Davis, Randy
Lewis, Nicole M.
Bakshi, Kalpana K.
Chopra, Bikramjit
de Oca, Rocio Montes
Ferron-Brady, Geraldine
Eliason, Laurie
Kremer, Brandon E.
Stowell, Delia
Gupta, Ira
Wu, Frank S.
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 177 - 177
[45] Results From the Randomized Phase 3 DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, Dexamethasone vs Pomalidomide Plus Bortezomib, Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma
Trudel, Suzanne
Beksac, Meral
Pour, Ludek
Delimpasi, Sosana
Vorobyev, Vladimir
Hang Quach
Spicka, Ivan
Radocha, Jakub
Robak, Pawel
Kim, Kihyun
Cavo, Michele
Suzuki, Kazuhito
Morris, Kristin
Pompilus, Farrah
Wilkes, Jodie
Philips-Jones, Amy
Zhou, Xiaoou
Fulci, Giulia
Sule, Neal
Kremer, Brandon
Opalinska, Joanna
Mateos Manteca, Maria-Victoria
Dimopoulos, Meletios
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S39 - S40
[46] Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM)
Hungria, Vania
Robak, Pawel
Hus, Marek
Fu, Chengcheng
Zherebtsova, Vera
Ward, Christopher
De Almeida, Ana Carolina
Ho, P. Joy
Hajek, Roman
Cerchione, Claudio
Pirooz, Nicholas
McKeown, Astrid
Baig, Hena
Eccersley, Lydia
Pompilus, Farrah
McNamara, Simon
Lin, Chee Paul
Roy-Ghanta, Sumita
Opalinska, Joanna
Mateos, Maria-Victoria
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[47] Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Salcedo, Meghan
Lendvai, Nikoletta
Mastey, Donna
Schlossman, Julia
Hultcrantz, Malin
Korde, Neha
Mailankody, Sham
Lesokhin, Alexander
Hassoun, Hani
Smith, Eric
Shah, Urvi
Diab, Victoria
Werner, Kelly
Landau, Heather
Lahoud, Oscar
Drullinsky, Pamela
Shah, Gunjan
Chung, David
Scordo, Michael
Giralt, Sergio
Landgren, Ola
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (03): : 198 - 200
[48] Very Low to Low Doses of Continuous Azacitidine in Combination with Standard Doses of Lenalidomide and Low-Dose Dexamethasone (Rd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Interim Results of a Phase I/II Study
Reu, Frederic J.
Khan, Shahper N.
Mahfouz, Reda Z.
Dean, Robert M.
Faiman, Beth
Reed, Janice
Karam, Mary Ann
Hamilton, Kimberly
Fada, Sherry
Kalaycio, Matt
Campagnaro, Erica L.
Kindwall-Keller, Tamila L.
Valent, Jason
Samaras, Christy
Sobecks, Ronald
Jirousek, Carolyn
Duong, Hien K.
Orloff, Mohammed
Saunthararajah, Yogen
BLOOD, 2012, 120 (21)
[49] A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Lonial, Sagar
Jakubowiak, Andrzej J.
Jagannath, Sundar
Raab, Marc S.
Facon, Thierry
Vij, Ravi
Moreau, Philippe
Reece, Donna E.
White, Darrell J.
Benboubker, Lotfi
Zonder, Jeffrey A.
Rossi, Jean-Francois
Tsao, Claire
Parli, Teresa
Kroog, Glenn
Singhal, Anil K.
Richardson, Paul G.
BLOOD, 2011, 118 (21) : 141 - 142
[50] Open-label, single-arm phase Ib/II study of immune combination therapy with elotuzumab and belantamab mafodotin in patients with relapsed refractory multiple myeloma
Browning, Sabrina
Li, Fangyong
Parker, Terri L.
Bar, Noffar
Anderson, Tara
Stevens, Erica
VanOudenhove, Jennifer
Matthews, Martin
Gorshein, Elan
Talsania, Ashita D.
Sabbath, Kert D.
Seropian, Stuart
Halene, Stephanie
Neparidze, Natalia
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →